%20Web.png)
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
- High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the...
Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
JERUSALEM, December 18th, 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
JERUSALEM, December 17th,2024-- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW ), ("Alpha Tau" or the "Company"), the developer of the...
Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones -...
Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to...
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
JERUSALEM, October 21, 2024 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...